Sanofi gets Philippines approval to market dengue vaccine in ASIA
Advertisement
Mumbai: Sanofi Pasteur, the vaccines division of Sanofi, said Food and Drug Administration of Philippines has granted marketing approval to its Dengvaxia vaccine to be licensed for the prevention of dengue in Asia.
The Philippines' FDA has approved Dengvaxia, the dengue vaccine for the prevention of disease caused by all four dengue types in individuals from 9-45 years of age living in endemic areas, Sanofi said in a statement.
The Philippines' FDA has approved Dengvaxia, the dengue vaccine for the prevention of disease caused by all four dengue types in individuals from 9-45 years of age living in endemic areas, Sanofi said in a statement.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.